Web www.software-risk.co.uk

EntreMed CEO and Biotechnology Industry Organisation (BIO) representative, James Burns, is to testify before the House Committee on Small Business about the effects of Sarbanes-Oxley.

The hearing centres on "Sarbanes-Oxley Section 404: What is the Proper Balance Between Investor Protection and Capital Formation for Smaller Public Companies?"

Burns wil focus on the infamous Section 404, claiming it imposes a one-size-fits-all approach to internal controls.

BIO is seeking regulatory reform through the Securities and Exchange Commission (SEC) rather than a legislative fix.

The Biotechnology industry is one of many hi-tech sectors seeking changes to the corporate governance law.

Related Articles
SEC Proposes Years Exemption on 404
WebFinancial Cites SOX in Delisting
COX - Sooner Rather than Later on SOX Reform
Caterpillar Calls for Lower Level 404
GAO Supports SOX Cost Claims
Panelists Named for Sarbanes-Oxley Roundable
SEC Chief Account Defends SOX
Small Company Recommendations for SOX

Similar Areas

Health & Social Care Items

Sarbanes-Oxley Items

Accounting Items

Regulation Items

US Government Items

Selected Books

Keywords

Sarbanes-Oxley lobbying

Sarbanes-Oxley and small business

small business

small companies

Section 404 reform

investor protection

capital formation

Sarbanes-Oxley and SEC

EntreMed

Biotechnology

biotechnology industry